Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

4,697.00ILa
10:24am EST
Change (% chg)

-104.00 (-2.17%)
Prev Close
4,801.00
Open
4,786.00
Day's High
4,867.00
Day's Low
4,660.00
Volume
874,060
Avg. Vol
1,317,209
52-wk High
15,010.00
52-wk Low
3,820.00

Chart for

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 1.20
Market Cap(Mil.): ₪44,738.22
Shares Outstanding(Mil.): 1,014.36
Dividend: 29.80
Yield (%): 7.03

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Teva announces prescription copay savings program for generic Gleevec tablets in the U.S.

* Teva announces prescription copay savings program for generic Gleevec® tablets in the United States Source text for Eikon: Further company coverage:

Nov 15 2017

Allergan to sell a quarter of its Teva stake in first quarter of 2018

NEW YORK Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

Nov 13 2017

Allergan to sell a quarter of its Teva stake in Q1 2018

NEW YORK, Nov 13 Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

Nov 13 2017

U.S. junk bond sector ends rough week on calmer note

NEW YORK Cracks in the red-hot U.S. high-yield bond market are starting to widen, with two junk-rated companies pulling their deals on Friday and U.S.-based high-yield funds suffering their second consecutive week of cash withdrawals.

Nov 10 2017

UPDATE 2-U.S. junk bond sector ends rough week on calmer note

* Doubts about U.S. tax plan, other news stoke sector sell-off

Nov 10 2017

Mylan raises forecast on strength of generic Copaxone

Mylan NV on Monday raised its full-year forecast and expects sales from its recently approved version of Teva's blockbuster multiple sclerosis treatment Copaxone to offset declining revenue from its EpiPen emergency allergy injector.

Nov 06 2017

UPDATE 3-Mylan raises forecast on strength of generic Copaxone

* Raises lower end of 2017 revenue, adjusts earnings forecasts

Nov 06 2017

Billionaire Blavatnik weighs big share purchase in Teva Pharm: reports

JERUSALEM Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries , according to Israeli media reports.

Nov 05 2017

UPDATE 1-Billionaire Blavatnik weighs big share purchase in Teva Pharm-reports

JERUSALEM, Nov 5 Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries, according to Israeli media reports.

Nov 05 2017

Billionaire Blavatnik weighs big share purchase in Teva Pharm-reports

JERUSALEM, Nov 5 Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries, according to Israeli media reports.

Nov 05 2017

Earnings vs. Estimates